Compare Hyatt Hotels Corporation (H) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyatt Hotels Corporation vs Repligen Corporation Common Stock — how do they compare? Hyatt Hotels Corporation trades at $160.32 (market cap $15.11B), while Repligen Corporation Common Stock trades at $178.2 (market cap $11.31B). The key difference: Hyatt Hotels Corporation is the larger of the two by market cap, and Hyatt Hotels Corporation pays a 0.37% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hyatt Hotels Corporation for 149 Days and Repligen Corporation Common Stock for 0 Days on average.
| H | RGEN | |
|---|---|---|
Market Cap | $15.11B | $11.31B |
Volume | 769,803 | 1,216,919 |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $194.57 |
52-Week Low | $135.42 | $102.87 |
Typical Hold Time | 149 Days | 0 Days |
Enterprise Value | $19.01B | $11.20B |
Dividend Yield | 0.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels (H) trades at $162.92, up 1.08% on the day, with a bullish technical signal and recent earnings beats in Q4 2025, Q1 2026, and Q2 2026. The stock is supported by a consensus price target of $197.92, representing a 21% upside, and positive news including a strategic loyalty collaboration with Delta Air Lines and portfolio expansion. However, valuation metrics like a P/E of 197.93 and a net income margin of 1.1% indicate premium pricing relative to modest profitability.
The outlook for H is cautiously optimistic, driven by earnings momentum and strategic initiatives, but high valuation and fluctuating cash flows pose risks. Investors should weigh the potential for continued operational growth against the stock's rich multiples and macroeconomic sensitivity in the hospitality sector.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
